Glycoprotein / GP (virus)

Glycoprotein / GP (virus) Overview

English NameEnvelope glycoproteinApproved Drugs2
Drugs in Clinical Trials2Target SynonymGP1,2,GP,Envelope glycoprotein
Highest Development StageApproved
English NameEnvelope glycoprotein
Target SynonymGP1,2,GP,Envelope glycoprotein
Approved Drugs2
Drugs in Clinical Trials2
Highest Development StageApproved

Product Inquiry

Glycoprotein / GP (virus) Background

EBOV encodes seven structural proteins: nucleoprotein (NP), polymerase cofactor (VP35), (VP40), GP, transcription activator (VP30), VP24, and RNA polymerase (L). GP protein contains 160-kDa envelope-attached glycoprotein (GP) and a 110 kDa secreted glycoprotein (sGP). GP is a class I fusion protein which assembles as trimers on viral surface and plays an important role in virus entry and attachment. Mature GP is a disulfide-linked heterodimer formed by two subunits, GP1 and GP2, which are generated from the proteolytical process of GP precursor (pre-GP) by cellular furin during virus assembly . GP1 is responsible for binding to the receptor(s) on target cells. Interacts with CD209/DC-SIGN and CLEC4M/DC-SIGNR which act as cofactors for virus entry into the host cell. GP2 acts as a class I viral fusion protein. GP1,2 mediates endothelial cell activation and decreases endothelial barrier function. sGP seems to possess an anti-inflammatory activity as it can reverse the barrier-decreasing effects of TNF alpha.

Glycoprotein / GP (virus) Synonyms

GP,Envelope glycoprotein,GP(1,2)

Clinical Drug Information

English NameResearch CodeHighest Development StageCompanyIndicationClinical Trial
Porgaviximab/Larcaviximab/Cosfroviximabc2G4-N; c4G7; c13C6Phase 3 ClinicalMapp Biopharmaceutical, Public Health Agency Of Canada'S National Microbiology LaboratoryHemorrhagic Fever, Ebola
Details
MIL-77MIL-77Phase 1 ClinicalBeijing Mabworks Biotech Co Ltd, Zhejiang Hisun Pharmaceutical Co Ltd, Institute Of Basic Medicine Academy Of Military Medical SciencesHemorrhagic Fever, Ebola
Details

Marketed Drug Information

English NameResearch CodeHighest Development StageCompanyEarliest Brand NameEarliest Approval CountryEarliest IndicationEarliest Approval CompanyEarliest Approval DateIndicationClinical Trial
AnsuvimabVRC-EBOMAB092-00-AB; MAb114; MAb-114ApprovedNational Institute Of Allergy And Infectious Diseases (Niaid), National Institute of Health, IslamabadEbangaUnited StatesHemorrhagic Fever, EbolaRidgeback Biotherapeutics Lp2020-12-21Hemorrhagic Fever, Ebola
Details
Atoltivimab/Maftivimab/OdesivimabREGN3470-3471-3479; REGN-EB3ApprovedRegeneron Pharmaceuticals IncInmazebUnited StatesHemorrhagic Fever, EbolaRegeneron Pharmaceuticals Inc2020-10-14Hemorrhagic Fever, Ebola
Details
  • Overview
  • Product Inquiry
  • Marketed Drug Information
  • Clinical Drug Information
Contact Us

전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521

주소 서울특별시 송파구 법원로11길 11, 제3층 제비-314,315호